PHP43 THE INFLUENCE OF PATIENT ACCESS SCHEMES ON APPRAISAL DECISIONS BY NICE IN THE UNITED KINGDOM  by Timm, B. et al.
likely to be little or no change in how this is managed. Conversely, in countries
where the orphan drug provision is integrated with the healthcare macro-struc-
ture, such as in the UK with the former regional Special Commissioning Groups,
this will likely change along with structural reforms to the overall system. Finally,
in markets where healthcare can be considered predominantly privately funded
(e.g. USA), unless there are changesmade to legislation, orphan drug provision and
funding are unlikely to be significantly affected in the future. CONCLUSIONS: De-
spite the issues of tightening budgets, restrictions on prescribing and structural
reform, orphan drug provision is unlikely to decrease from current levels, but bud-
getary constraints may make the future landscape more hostile to drugs for new
orphan indications.
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OBJECTIVES: Although the Medicare Part D benefit has helped improve prescrip-
tion medication access and lower out-of-pocket spending for some, variability in
drug cost and access restrictions of Part D plans continues to present a challenge
for others. The present research sought to examine the reported drug cost and
restrictions (Step Therapy (ST), Quantity Limits (QL), Prior Authorization (PA), and
Formulary Coverage) associated with each of the 100 (65 generic and 35 brand
name) most commonly filled drugs by Medicare beneficiaries under every stand-
alone prescription drug plan (PDP) available in California in 2011. METHODS: The
list of the top 100 Drugs by total fills under Part D plans in 2008 was retrieved from
the Centers for Medicare &Medicaid Services. Each of these drugs was entered into
the Medicare Plan Finder Tool (www.medicare.gov). Data found via use of the Plan
Finder Tool revealed the full cost, formulary coverage and restriction processes of
every examined drug under each of the 2011 California PDPs for which data were
available. RESULTS: The difference between the lowest and highest plan reported
full cost of each generic (brand) drug from all available PDPs ranged from a low of
$3.37 ($5.41) to a high of $134.34 ($106.33). In addition, differences were found
between generic and brandmedications in terms of drug restrictions (3.08% generic
vs. 57.1% brand drugs required ST), (58.46% generic vs. 94.3% brand drugs required
QL) and (4.62% generic vs. 31.4% brand drugs required PA) across the PDPs. Finally,
13 (20%) generic and 25 (71.4%) brand-name drugswere not covered on one ormore
PDP formularies. CONCLUSIONS: Significant differences in medication costs and
plan imposed restriction processes exist between the various 2011 California PDPs.
Such differences may present additional barriers to Part D plan access and poten-
tially impact health-related outcomes and costs of Medicare beneficiaries.
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OBJECTIVES: Patient Access Schemes (PAS) have become increasingly important in
technology assessment by NICE; a previous ISPOR abstract showed an increase in
PAS inclusion in submissions from 0 in 2006 to 29% in 2009. However, concerns
have been raised regarding the increasing complexity and the suitability of these
schemes compared to other cost-containment methods. We aimed to evaluate the
influence of including PAS on appraisal decisions by NICE, and consider the impact
that this could have on future submissions. METHODS: All NICE technology ap-
praisals published in 2010 and appraisals in development were reviewed. Submis-
sions in which a PAS was included were identified; PAS were defined as the man-
ufacturer providing a pre-defined reduction in overall cost of treatment through
risk-sharing or rebate schemes. RESULTS: Of the technology appraisals published
by NICE in 2010, 24% (6/25) included a PAS. Of the appraisals in development for
which a final appraisal determination has been published, 44% (7/16) included a
PAS, either in the original submission or in the revised manufacturer’s model.
Oncology products represented 10 of the 13 (6 published  7 in development)
submissions identified. Of these 13 submissions, 3 published in 2010 received a
negative appraisal, along with 4 of the appraisals in development (subject to ap-
peal). In the majority of these cases, even when the PAS was included in the eco-
nomic model the proposed ICER was still above the assumed willingness-to-pay
(WTP) threshold of £30,000 per QALY. Excessive administrative burden of imple-
menting the PAS was also noted in one rejected submission. CONCLUSIONS: PAS
are an increasingly important element of NICE submissions to enhance the cost-
effectiveness of innovative drugs. Negative appraisal decisions made on submis-
sions including PAS highlight howmanufacturersmust ensure that these schemes
are easy to implement and enhance cost-effectiveness to a level deemed accept-
able by NICE, in order to positively influence appraisal decisions.
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OBJECTIVES: This study explores the duration that patients stay in the emergency
department (ED) for visits where they are treated and released. Duration for treat-
and-release (T&R) ED visits is assessed by admission day and hour, patient demo-
graphics and hospital characteristics. METHODS: A retrospective data analyses
was conducted to characterize the duration of T&R ED visits. Duration for each visit
was computed by taking the difference between admission and discharge times.
Sensitivity analyses were performed to assess the robustness of results. The
Healthcare Cost and Utilization Project (HCUP) State Emergency Department Data-
bases (SEDD) for 2008 were used in the analysis. The SEDD employed in this study
include 4.7 million T&R ED visits in Arizona, Massachusetts, and Utah. RESULTS:
Duration varied significantly across admission hour and day of the week. At 95th
percentile, the average duration of T&R ED visits were longer (197.8 – 202.6, min-
utes). The average duration for patients admitted at 8 a.m. on Mondays, other
weekdays, andweekendwere respectively 184, 189, and 172minutes. Similarly, the
average duration for patients admitted at 4 p.m. (12a.m.) on Mondays, other week-
days, and weekend were respectively 210, 202 and 179 (231, 246 and 234) minutes.
Medicare patients have the longest average duration (238 minutes). Black patients
have 22minutes longer duration compared towhite patients. Therewas significant
variation in average duration across disease groups (e.g., 284 minutes for mental
disorders and 160 minutes for injury and poisoning related diseases). The average
duration at teaching (non-teaching) hospitals was 225 (166) minutes. Hospitals
with large bed sizewere associatedwith the longest duration of visits (222minutes)
when compared to hospitals with small bed size (172 minutes). CONCLUSIONS:
The duration of T&R ED visits varied significantly across patient characteristics,
hospital characteristics, admission hour, and day of the week.
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OBJECTIVES: Those patients visited toward a single hospital loyally have ac-
counted for 3.5% of all beneficiaries and consumed 19.3% of covered medical ex-
penditure under Taiwan’s National Health Insurance (NHI) program. This study
was to examine the trends of service utilization, medical expenditure and disease
patterns among loyal patients visited toward China Medical University Hospital
(CMUH), a 2000-bed medical center in Taiwan. METHODS: Patients’ visits made
toward CMUH accounted for more than 50% of their total outpatient visits in Tai-
wan during January 2008 to June 2009 (retrospective period) were assigned as
CMUH loyal patients by Bureau of NHI. The corresponding data documented in
CMUH from January 2008 to April 2010 were retrieved and analyzed. Those as-
signed loyal patients persistently visited CMUHduring July to September 2009were
grouped into four levels of utilization base upon their numbers of outpatient de-
partment (OPD) visits made toward CMUH during retrospective period. The com-
parisons of disease statuses, healthcare utilization, medical expenditure and visits
toward different specialties among different utilization groups and across different
study periods in CMUH were made. RESULTS: 11,846 CMUH loyal patients were
groups into four levels of OPD utilization (20, 2123, 2435, 36) during 18
months (mean OPD visit 1.83/person/month). Those loyal patients used more
OPD visits were elder, more co-morbidities, taken care by more physicians and
medical specialties, and prescribed more medications. The more visits made to-
wardOPD, the higher likelihood to consumemoremedical expenditures and utilize
more medical resources in CMUH. Although more than 75% of OPD visits were
made toward one or two medical departments, more medical resources in CMUH
were attributable to those patients visited more than three medical specialties.
CONCLUSIONS:Results suggest in-house programs to facilitate integrated care and
medication reconciliation toward high utilization loyal patients are more de-
manded than other loyal patients in CMUH.
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OBJECTIVES: The study assessed the state of health economics (including phar-
macoeconomics) research in South Africa.METHODS: A literature search was con-
ducted to identify health economics articles pertaining to South Africa. Two re-
viewers independently scored each article in the final sample using the data
collection form designed for the study. RESULTS: In total, 108 studies investigating
awide variety of diseaseswere included in the study. These articleswere published
in 39 different journals mostly based outside of South Africa between 1977 and
2010. On average, each article was written by four authors. Most first authors had
medical/clinical training and resided in South Africa at the time of publication of
the study. Based on a 1 to 10 scale, with 10 indicating the highest quality, themean
quality score for all studieswas 7.59 (SD 1.42) and half of the articles were of good
quality (score 8-10) The quality of studies was related to the country in which the
journal publishing the article was based (outside South Africa  higher), current
residence of the primary author (outside South Africa  higher), method of eco-
nomic analysis (economic evaluations higher than cost studies), type of data used
(secondary higher than primary), primary training of the first author (health eco-
nomics/pharmacoeconomics  higher), type of medical function (diagnosis 
higher), study perspective (society  higher), primary health intervention (phar-
maceuticals  higher), study design (modeling  higher), number of authors
(more  higher), and year of publication (more recent  higher) (p  0.05).
CONCLUSIONS: Half of the articles were of poor or fair quality. Measures are
needed to promote the commissioning of more and better quality health econom-
ics and pharmacoeconomics studies in South Africa.
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